Company ProfilePremium

Remgro Limited

Company Profile Analysis

Ticker: REM.JO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Remgro Limited - Company showcase

Year Founded & Workforce

1940

173 Employees

Remgro Limited logo

Remgro Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Remgro Limited Overview

Remgro is the Rupert family-controlled investment holding company that houses the family's South African industrial, financial and infrastructure interests. It is the domestic sibling of Richemont (luxury) and Reinet (international investments). Its portfolio is concentrated in assets that are hard to replicate in South African public markets. These include full ownership of Mediclinic Southern Africa (from 1 July 2026), a 57% controlling stake in the CIVH fibre group (Vumatel, Dark Fibre Africa), now co-owned at the Maziv level with Vodacom, and roughly 30% of OUTsurance Group. Food and consumer holdings include Rainbow, RCL Foods, Siqalo Foods and Heineken Beverages; industrial joint ventures include Air Products SA and TotalEnergies SA. Since 2020, a "simplify, optimise, focus" strategy has moved the portfolio away from listed holdings that investors can buy directly. Remgro exited FirstRand and British American Tobacco (BAT), unbundled Grindrod and eMedia, and took Mediclinic private. Remgro enters FY2027 with record headline earnings, roughly R20bn of net cash at the centre, and a persistent 30–45% discount to INAV.


What Remgro does

Pillar (company reporting platform)Principal current holdings (status Oct 2026)
HealthcareMediclinic Southern Africa (100% from 1 Jul 2026). Joint 50/50 holding with MSC in the Middle East business (EHH Group) and in the Spire Healthcare minority stake
Consumer productsRCL Foods (c.79.6%), Rainbow Chicken (c.80.0%), Siqalo Foods (100%), Heineken Beverages (c.18.8% effective), Capevin
Financial servicesOUTsurance Group (c.30.6%), Business Partners, minority stakes in Discovery (c.7.8% per Profile) and Momentum
InfrastructureCIVH (57.0%), which owns 70% of Maziv (Vumatel, Dark Fibre Africa, interest in Herotel) alongside Vodacom's 30%; SEACOM
IndustrialAir Products South Africa (50%), TotalEnergies Marketing South Africa (24.9%), Wispeco (100%)
Media & sporteMedia unbundled September 2025. Sport and social-impact interests remain (e.g., Blue Bulls, Stellenbosch FC, Stellenbosch Academy of Sport)
Diversified investment vehiclesKagiso Tiso Holdings (43.5%) and other funds/vehicles with a focus on South Africa and China (per Old Mutual Aperture research, Mar 2026)
Social impactSport and community investments
Central treasuryCash at the centre: R20.4bn at 30 Jun 2026, R22.5bn post year-end (Remgro FY2026 results presentation, per Quartr)

Remgro is a diversified, long-horizon investment holding company. It does not run a single operating business. Instead it acquires, controls or co-controls, and actively manages stakes in South African and selected international businesses.

The company's own description in its Profile's Handbook entry and annual reporting covers four points:

  • The portfolio has evolved substantially since its 1940s founding.

  • It now spans nine reporting pillars.

  • Its interests are mainly in healthcare, consumer products, financial services, infrastructure, industrial and media.

  • The most significant investments contribute about 88% of INAV after tax. At the last Profile disclosure, these were Mediclinic, OUTsurance Group, CIVH, Heineken Beverages, RCL Foods, Rainbow, FirstRand, Discovery, Siqalo Foods, Air Products, TotalEnergies and Kagiso Tiso Holdings (KTH).

FirstRand has since been fully sold and eMedia unbundled. The pillar structure therefore now consists of the following:

Stake percentages are the latest available in Profile's Stock Exchange Handbook (2026 Issue 1, reflecting 30 June 2025 disclosures) and press coverage. Stakes may have changed since; FY2026 IAR percentages were not available this cycle.

Business and revenue model

Revenue typeShare of value creationNotes
Product revenue (consolidated subsidiaries)~100% of IFRS revenueSold through FMCG retail/wholesale channels (RCL, Rainbow, Siqalo) and industrial/construction channels (Wispeco)
Service revenue (look-through)Large share of INAVHospitals (Mediclinic), insurance (OUTsurance), wholesale fibre (Maziv), industrial gases (Air Products)
Subscription/annuity (look-through)MaterialInsurance premiums, fibre access lines, gas supply contracts
LicensingNot material—

Remgro's "revenue" in the economic sense has four layers:

  1. Dividends from investees. Sustainable dividends of R2.428bn in H1 FY2026 (+34%), excluding a once-off CIVH pre-implementation dividend (Business Day, 25 Mar 2026).

  2. Interest income on central cash. This rose in FY2026 on the back of FirstRand sale proceeds.

  3. Realisations. Disposals (FirstRand R8.47bn; BAT R1.21bn) and corporate-action distributions (CIVH pre-implementation dividend).

  4. Consolidated product revenue from controlled subsidiaries. Food, poultry, edible oils and spreads, aluminium extrusions and Scotch whisky (R51.0bn in FY2026).

Mix characterisation (independent).

Value chain position. Remgro is a capital provider and active owner. It sits above its operating companies and provides capital allocation, board control or joint control, deal-making (e.g., Maziv–Vodacom, Mediclinic restructuring), executive appointments and central services.

Customer types and end-markets (look-through).

  • South African consumers: food, poultry, spreads, beer and spirits, personal and vehicle insurance, fibre-to-the-home.

  • Patients and medical schemes: private hospitals.

  • Telecoms operators and ISPs: wholesale open-access fibre.

  • Industrial customers: oxygen, nitrogen, argon, hydrogen and CO₂.

  • Fuel retail and commercial customers: TotalEnergies.

  • Construction and engineering: aluminium extrusions.

Independent characterisation. Remgro is best understood as a South Africa-centric, family-controlled permanent-capital vehicle. It is moving from a listed-share "fund of stakes" toward an unlisted, control-oriented portfolio. According to CEO commentary reported from the 2025 Integrated Annual Report, about 77% of the portfolio was JSE-listed in 2020. The thesis is to replace exposure investors can replicate with assets accessible only through Remgro. The FY2026 transactions (FirstRand exit, Mediclinic SA full ownership, Maziv co-control with Vodacom) largely complete that pivot.

Strategy

Stated strategy (paraphrased from company communications)

  1. "Simplify, optimise and focus" (adopted around 2020). Narrow the portfolio to fewer, larger and more controllable assets, and remove listed stakes that investors can hold directly. By September 2025 the board stated that a more focused investment thesis was beginning to emerge from the results (IOL, Sep 2025).

  2. Shift to private, control or co-control assets. About 77% of the portfolio was JSE-listed in 2020. Each disposal of listed exposure (FirstRand, BAT, eMedia, Grindrod) and each privatisation (Mediclinic, MCSA) moves toward "assets only available through Remgro" (africa.com, citing the 2025 Annual Report).

  3. Active partnership and ownership. Remgro pairs with strategic partners (MSC in healthcare, Vodacom in fibre, Heineken in beverages, Air Products in gases) and intervenes in performance (e.g., the RCL restructure).

  4. Disciplined capital allocation. Cash at the centre is treated as "strategic cash resources" managed under a capital allocation framework (Remgro SENS, Mar 2026). The ordinary dividend is set at 1.5x adjusted FCF cover, with special dividends from realisations (200c in FY2025 linked to BAT; 550c in FY2026).

  5. Next phase: value unlock and compounding (FY2026 onward). Management states that portfolio transformation is substantially complete. The focus now moves to converting the reshaped portfolio into measurable value creation (Business Day, Sep 2026; Quartr). AI is cited as a lever for executing strategy across the portfolio.

Strategic initiatives register (last 24 months)

InitiativeDateDescriptionStatus
Vodacom/Maziv co-controlImplemented 1 Dec 2025Fibre consolidation with a strategic telco partnerCompleted
Mediclinic restructuringAgreed 30 Mar 2026; implemented 1 Jul 2026Full ownership of MCSA; exit from HirslandenCompleted
FirstRand exitFeb–Apr 2026Disposal of non-core listed bank stake (R8.47bn)Completed
BAT exitFY2025–Sep 2025Disposal of residual tobacco stakeCompleted
eMedia unbundling29 Sep 2025Distribution of the c.35% stake to shareholdersCompleted
Capital Markets Day2,025Articulation of the private-asset, active-management modelCompleted
Special dividendsSep 2025; Sep 2026Return of realisation proceedsEx-date for the FY2026 special dividend: 21 Oct 2026
Board renewal2,02512-year independence rule; new Deputy Chair; Ramon appointmentOngoing
RCL Foods strategic optionsSpeculativeMarket speculation about a minority buyout, sugar separation or a merger with Siqalo (Financial Mail, Mar 2026)Unconfirmed — not announced by Remgro
AI enablement across portfolioFY2026 resultsStated management priorityEarly stage; no quantified targets disclosed

Medium-term targets / guidance

Dividend policy: 1.5x adjusted free cash flow cover (maintained at FY2026).

  • No explicit HE, INAV growth or discount-to-INAV targets were disclosed in the sources reviewed.

  • Mediclinic, OUTsurance and other investees provide their own guidance; it is not aggregated by Remgro.

Products & Services

Because Remgro's "products" are its investee businesses, this section catalogues each investee, its offerings and named brands. Pricing models are generally not disclosed at Remgro level.

Healthcare

Metric (USD Mn unless %)FY Mar 2026
Adjusted revenue5,356
Adjusted revenue growth %11
Adjusted EBITDA842
Adjusted EBITDA growth %14
Adjusted EBITDA margin %15.7
Adjusted earnings345
Adjusted earnings growth %45
Statutory net loss-733
Impairments (restructuring-related)555
Impairments (Swiss PPE and intangibles, before tax)689

Mediclinic Southern Africa (MCSA) — 100% owned from 1 July 2026

Description: private acute-care hospital and day-case network.

Footprint: around 50 private hospitals across South Africa and Namibia (BusinessTech, Sep 2026). Namibian hospitals include Windhoek, Swakopmund and Otjiwarongo (The Namibian, 2023).

Acquisition price: $947m (about R15.31bn) under the restructuring with MSC's IHL.

Performance (six months to 30 Sep 2025): - Revenue +8%, driven by volume growth and mix.

  • EBITDA margin up 70bp to 18.5%.

  • Occupancy flat.

Target customers: medical-scheme members and private-pay patients.

Pricing model: tariffs negotiated with medical schemes.

Mediclinic Middle East (EHH Group) — jointly held 50/50 with IHL

Description: hospitals and clinics in the UAE (Dubai and Abu Dhabi).

Performance (H1 to Sep 2025): revenue +11% on strong admissions; EBITDA margin 16.9% (+270bp).

Risk: the 2026 Middle East conflict complicated the operating environment.

Spire Healthcare (UK) minority stake — jointly held

  • Mediclinic historically held about 29.9% of Spire.

Hirslanden (Switzerland) — exited 1 July 2026

  • Transferred 100% to IHL for $1,077m.

  • Remgro received a $130m cash equalisation distribution.

  • Before the exit, Hirslanden revenue was flat in H1 FY2026, with EBITDA margin +170bp.

  • Large impairments were taken in FY2026.

Combined Mediclinic Holdings, year to 31 March 2026 (voluntary summary published by Remgro, 29 May 2026):

Source: FilingReader summary of Remgro SENS (29 May 2026). The prior year's Swiss impairments were $279m.

Consumer products

DivisionOfferingsNamed brands (public brand portfolio; not re-verified individually)
GroceriesSpreads, condiments, rusks, pet food, beveragesNola, Yum Yum, Ouma, Bobtail, Mister Sweet
BakingBread and bunsSunbake
SugarIrrigated cane sugar production (Selati), refined and brown sugarSelati

RCL Foods (c.79.6%) — JSE-listed

Groceries scale: RCL's groceries business has revenue of about R5.5bn (Financial Mail, Mar 2026).

Sugar division: this was the largest EBITDA contributor in H1 FY2025 (R750m). In H1 FY2026 Selati's profit fell 49% as margins halved under a flood of cheap imports (Financial Mail, Mar 2026).

Portfolio history: Vector Logistics was sold (Aug 2023, R1.25bn) and Rainbow unbundled (Jun 2024).

Pricing model: FMCG wholesale and retail.

Rainbow Chicken (c.80.0%) — JSE-listed since June 2024

Description: integrated poultry producer (broiler chicken, processed chicken) plus the Epol animal feed business.

FY2025 revenue: R15,838m.

H1 FY2026 performance: headline earnings +109–110% on 11% revenue growth, lower feed input costs and a stronger rand.

Contribution to Remgro FY2026 HE: +R610m.

Siqalo Foods (100%)

Description: edible fats, spreads and oils.

Financials: FY2025 revenue R3,715m. H1 FY2026 headline earnings −7% on volumes −2.7%, with stable margins after early-year price increases.

Valuation: Remgro valued Siqalo at R6.1bn (Financial Mail, Mar 2025).

Heineken Beverages Holdings (c.18.8% effective)

Description: Southern African beer, cider, spirits and wine business, majority-owned by Heineken.

Recovery: returned to profitability in FY2025 (+R406m swing). Further +R161m in FY2026, with strong beer momentum and margin expansion.

Capevin

  • Holds the former Distell remaining assets outside Heineken Beverages, including the Scotch whisky business.

  • FY2025 revenue R1,923m (FY2024: R2,659m).

Financial services

OUTsurance Group (c.30.6%) — JSE-listed

Description: direct short-term (non-life) insurance in South Africa, Youi in Australia, and international expansion. Also offers life insurance.

H1 FY2026: normalised earnings +12.6%, with SA strength partly offset by higher Youi claims.

FY2026 contribution change: +R332m to Remgro HE.

Business Partners

Description: specialist SME investment company providing finance, mentorship and property management services to small and medium enterprises.

Minority listed stakes

  • Discovery (c.7.8% per Profile 2026) and Momentum Group (percentage not disclosed in the sources reviewed).

  • FirstRand: fully exited April 2026.

Infrastructure

AssetOfferingNotes
VumatelOpen-access fibre-to-the-home (FTTH)H1 FY2026 revenue +15.4%
Dark Fibre Africa (DFA)Metro and long-distance open-access fibre, business and transmission backhaulH1 FY2026 revenue +3.6%
Vodacom fibre assets contributedFTTH, FTTB and B2B transmission infrastructureValued at R4.9bn on contribution
HerotelRegional/rural fibre and fixed-wireless ISP; Maziv holds about 49.9%Vodacom paid about R0.6bn for its look-through share

CIVH (57.0%), which owns 70% of Maziv (30% held by Vodacom since 1 Dec 2025)

Pricing model: wholesale access fees to ISPs and operators; annuity-type revenue.

Valuation: the transaction valued Maziv at about R36bn pre-money (R29.8bn after the pre-implementation dividend) and the combined entity at over R47bn (Daily Investor; BusinessTech).

SEACOM

Description: subsea fibre-optic cable system serving Southern and East Africa. Provides international wholesale bandwidth and enterprise connectivity.

Industrial

Air Products South Africa (50%)

Description: joint venture with Air Products & Chemicals Inc. (US). Produces oxygen, nitrogen, argon, hydrogen and CO₂.

Pricing model: pipeline/onsite supply contracts and bulk/cylinder sales.

Performance: H1 FY2026 earnings +11% on volumes and margins.

TotalEnergies Marketing South Africa (24.9%)

Description: fuel and lubricants marketing and retail network.

FY2026: contribution rose R424m. This includes a once-off Transnet pipeline cost refund (Remgro's share R218m) and positive stock revaluations. Results were partly offset by refinery supply constraints.

FY2025: contribution fell R359m on negative stock revaluations.

Wispeco (100%)

Description: aluminium extrusions manufacturer and distributor for the building, engineering and durables sectors.

FY2025 revenue: R3,909m.

Other platforms

Media & sport: eMedia (e.tv, eNCA, Openview) unbundled on 29 September 2025. Remaining sport interests include Blue Bulls rugby, Stellenbosch FC and the Stellenbosch Academy of Sport (Daily Investor, Apr 2026).

Diversified investment vehicles: - Kagiso Tiso Holdings (43.5%): a black-owned investment holding company.

  • Other vehicles with exposure to South Africa and China (Old Mutual Aperture, Mar 2026). Individual vehicles were not enumerated in the sources reviewed.

Financial Narrative

Primary sources: Remgro audited results SENS (FY2025: 23 Sep 2025; FY2026: 18 Sep 2026), Profile's Stock Exchange Handbook (2026 Issue 1), and S&P Global Market Intelligence standardised statements via StockAnalysis (updated 18 Sep 2026). S&P standardisation may differ slightly from company-presented line items. Where they differ, both are noted.

Company performance measures (management basis)

Notes:

FY2022–FY2023 INAV per share: are derived from the disclosed discount to INAV (39.0% and 40.8%, per the FY2023 AFS) and the closing share prices (Profile's Handbook).

FY2026 price and discount: are derived (S&P closing price; 1 − 197.00/305.80). The company-reported FY2026 discount was not available.

FY2022 HE growth: is taken from Profile's 106.0% HEPS growth; HE growth is derived from FY2021 HE of R2,885m.

FY2024 HE: Profile shows R5,646m, the FY2025 SENS shows R5,647m (rounding).

Adjusted HEPS: FY2026 is per the results presentation (Quartr).

INAV total growth including distributions: in FY2026 was 8.9%.

Income statement (IFRS, S&P standardised)

Margins (%)

Growth (derived):

  • Revenue CAGR FY2022→FY2026 ≈ 5.1%.

  • Headline earnings CAGR FY2022→FY2026 ≈ 17.6%.

  • HEPS CAGR FY2022→FY2026 ≈ 18.1%.

  • Ordinary DPS CAGR FY2022→FY2026 ≈ 41.1%.

Commentary: revenue.

  • Consolidated revenue is essentially flat (+0.3% in FY2025, +0.9% in FY2026).

  • The flatness reflects RCL's weak sugar business and price deflation in poultry inputs, offset by Rainbow volume growth.

  • The FY2022 drop reflects Distell's deconsolidation (FY2021 revenue R65.8bn).

  • Revenue is not a meaningful measure of Remgro's economic performance.

Commentary: margins.

  • Gross margin expanded to 39.9% in FY2026 and operating margin to 7.5%, from 5.0% in FY2022.

  • Drivers: Rainbow's recovery (lower feed costs, stronger rand) and cost discipline at RCL Groceries and Siqalo. Sugar margin compression was a partial offset.

Commentary: the headline-earnings vs IFRS divergence (the key FY2026 inflection).

  • HE rose 42.3% to R11.14bn, but IFRS EPS fell about 56.5% to R2.59.

  • The cause is Remgro's share of Mediclinic's FY2026 impairments of Hirslanden (Switzerland). Mediclinic recorded $1.24bn of impairments in its year to March 2026: $555m restructuring-related and $689m on Swiss assets.

  • This is why S&P shows a negative R1,771m equity-accounted line.

  • Impairments are excluded from HE under JSE headline earnings rules.

Once-offs: HE included about R1.02bn of material once-off items. Excluding these, HE grew 29.3% to R10.1bn. The largest disclosed once-off is the TotalEnergies Transnet pipeline refund (Remgro share R218m).

FY2024 trough: HE −15% and IFRS net income R1.24bn reflect Heineken Beverages losses and the impairment of the Distell/Heineken goodwill. A R3.88bn loss on investments is shown in S&P data.

Commentary: finance costs. Interest expense fell from R1.0bn (FY2023) to R0.39bn (FY2026) following redemption of preference shares. This was worth R403m to FY2025 HE.

Balance sheet

Source: S&P Global via StockAnalysis (18 Sep 2026). Short/long-term debt splits are derived by summing S&P components. Profile's Handbook shows FY2023 attributable equity of R115,267m vs S&P's R115,920m; the difference is a restatement or classification. "Cash at the centre" (company measure) was R20.4bn at 30 June 2026 (+143.6%) and R22.5bn post year-end. This differs from consolidated cash, which includes subsidiary cash.

Balance sheet commentary.

  • Remgro has de-geared decisively, from total debt of R15.6bn (FY2022) to R4.9bn (FY2026). The company is now in a R20.7bn consolidated net cash position.

  • The FY2026 jump in cash reflects four inflows:

    • FirstRand disposals (R8.47bn).

    • The BAT sale (R1.21bn).

    • The CIVH pre-implementation dividend.

    • Strong dividend receipts.

  • The decline in long-term investments (R89.6bn to R78.9bn) reflects:

    • Removal of the FirstRand fair-value stake.

    • The eMedia distribution.

    • Mediclinic's equity-accounted carrying value reduced by Swiss impairments.

  • After 1 July 2026, Remgro paid $947m (about R15.3bn) for MCSA and received a $130m distribution. Part of this was settled through restructuring mechanics (the "MCSA Loan" referenced in the SENS), so the net cash impact is not fully disclosed. Management nonetheless reported cash at the centre rising to R22.5bn post year-end. Readers should expect the FY2027 balance sheet to show MCSA consolidated (adding hospital assets, debt and goodwill).

Cash flow

Source: S&P Global via StockAnalysis. FY2026 OCF, capex, FCF and net borrowing are from the S&P statistics page (Oct 2026); FY2026 dividends paid and buybacks were not available in a verified annual statement. Company FCF at the centre FY2026 (R8.31bn, +105.6%) and adjusted per share (891c, +28.6%) are from Remgro's FY2026 results via Daily Investor and Quartr. FY2025 FCF-at-centre values are derived (8,310/2.056; 891/1.286).

Cash flow commentary.

Dividend receipts: these rose 104.4% in FY2026, including the once-off CIVH pre-implementation dividend.

  • R2.06bn (Daily Investor, FY2026 results article).

  • R2.66bn received on implementation (Business Day, interim results).

  • About R2.7bn (Old Mutual Aperture).

  • R3.06bn in total (Daily Investor, later article). The R2.66bn figure, attributed to the interim results, is the most specific. The R2.06bn may reflect the portion classified in FY2026 FCF after adjustments.

Dividend policy: management maintains an ordinary dividend cover of 1.5x adjusted free cash flow at the centre. FY2026 is consistent: 891c / 595c ≈ 1.50x.

Ratios

Source: S&P Global via StockAnalysis, and derived. The cash conversion cycle was not computed by the company or by S&P in the sources reviewed. Profile's Handbook reports differently defined ratios, e.g., FY2025 return on shareholders' funds 2.57% and current ratio 3.74.

Ratio commentary.

  • IFRS returns are structurally low and volatile for an investment holding company carrying equity-accounted stakes at cost plus retained earnings. They are not the right yardstick.

  • Better measures:

    • HE return on equity: rose from 5.0% (FY2024) to 9.3% (FY2026).

    • INAV per share total return including distributions: 8.9% in FY2026.

    • INAV per share CAGR FY2024→FY2026: about 10.4%.

Liquidity: exceptional, with a current ratio of 5.3x and net cash of about 4x EBITDA. This provides optionality for both reinvestment and distributions.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment revenue (ZAR Mn)

Segment revenue (ZAR Mn)FY2022FY2023FY2024FY2025FY2026

RCL Foods (FY2022–FY2024 incl. Rainbow)

32,20137,78340,51126,494—

Rainbow

———15,838—

Capevin

-14212,6591,923—

Siqalo Foods

3,5463,7483,5943,715—

Wispeco

3,5983,8133,7593,909—

Other segments

747790-111—

Inter-segment eliminations

-163-167-189-262—

Total consolidated revenue

41,87548,15150,42451,50651,010

Segment Revenue

SegmentFY2024→FY2025 growth %FY2025 share of revenue %

RCL Foods + Rainbow (combined, like-for-like)

4.582.2

Capevin

-27.73.7

Siqalo Foods

3.47.2

Wispeco

4.07.6

Platform Details

Platform% of INAV (HY2026)Key holdings

Healthcare

24.4

Mediclinic

Financial services

20.6

OUTsurance Group, Business Partners, minority listed stakes

Consumer products

15.5

RCL Foods, Rainbow, Siqalo, Heineken Beverages, Capevin

Infrastructure

10.0

CIVH (Maziv), SEACOM

Industrial

7.4

Air Products SA, TotalEnergies SA, Wispeco

Cash, other investments, diversified vehicles, central (derived residual)

22.1

Central cash R12bn at 31 Dec 2025 plus remaining FirstRand (sold Feb–Apr 2026), KTH and other

Change in headline earnings contribution (ZAR Mn)

Change in headline earnings contribution (ZAR Mn)FY2025FY2026

Mediclinic

3621,370

Rainbow Chicken

324610

CIVH

—412

OUTsurance Group

318332

Heineken Beverages

406161

TotalEnergies SA

-359424

RCL Foods

264—

Lower finance costs (preference share redemption)

403—

Key Financials and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Headline earnings (ZAR Mn)

5,8166,6425,6477,82711,140

Headline earnings growth %

101.614.2-15.038.642.3

HEPS (ZAR cents)

1,0311,1801,0181,4092,003

HEPS growth %

106.014.5-13.738.442.2

Adjusted HEPS excl. once-offs (ZAR cents)

————1,819

INAV per share (ZAR)

208.7248.4251.01292.34305.80

INAV per share growth %

—19.01.016.54.6

Closing share price at 30 June (ZAR)

127.32147.05136.09158.20197.00

Discount to INAV %

39.040.845.845.935.6

Total INAV (ZAR Bn)

——139.3162.5—

Income statement (ZAR Mn)

Income statement (ZAR Mn)FY2022FY2023FY2024FY2025FY2026

Revenue

41,87648,15150,42450,55951,010

Revenue growth %

-36.415.04.70.30.9

Gross profit

15,81017,33918,23818,89420,365

Operating income (EBIT)

2,1092,3162,6803,0873,817

EBITDA

4,3824,2033,6644,1914,981

Earnings from equity-accounted investments

10,7863,2962,7991,617-1,771

Interest expense

8871,002933503387

Interest and investment income

1,0232,1461,6461,4921,753

Pre-tax income

13,5846,5352,2304,1433,002

Income tax

7578329489571,170

Net income attributable to shareholders

13,1399,6241,2413,3031,438

EPS basic (ZAR cents)

2,3281,710224595259

EPS diluted (ZAR cents)

2,3131,696218586252

Ordinary dividend per share (ZAR cents)

150240264344595

Special dividend per share (ZAR cents)

000200550

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

37.7536.0136.1737.3739.92

Operating (EBIT) margin

5.044.815.326.117.48

EBITDA margin

10.468.737.278.299.77

Net margin

31.3819.992.466.532.82

Effective tax rate

5.5712.7342.5123.1038.97

Balance Sheet and Per-Share Data

Balance sheet (ZAR Mn)FY2022FY2023FY2024FY2025FY2026

Total assets

156,698150,965139,178142,174144,875

Cash and equivalents

11,8846,0476,7898,85514,933

Cash and short-term investments

17,58410,6299,48812,23125,636

Short-term debt (incl. current LTD and leases)

2,9286,6274,671346341

Long-term debt (incl. leases)

12,7036,3271,9524,4824,566

Total debt

15,63112,9546,6234,8284,907

Net debt (negative = net cash)

-1,9532,325-2,865-7,403-20,729

Long-term investments (associates, JVs, other)

71,66399,15990,08589,56278,913

Goodwill

7,9707,0847,0736,3076,189

Other intangibles

12,3053,5813,5543,5943,241

Goodwill and intangibles

20,27510,66510,6279,9019,430

Inventory

13,5687,8328,4979,34110,280

Total current assets

45,70930,35126,81529,91143,281

Total current liabilities

19,69016,73712,9847,8768,169

Working capital

26,01913,61413,83122,03535,112

Shareholders' equity attributable

98,443115,920112,117117,039120,291

Minority interest

17,4376,5217,0476,8406,833

Total equity

115,880122,441119,164123,879127,124

Book value per share (ZAR)

174.52207.51202.04210.55216.07

Cash flow (ZAR Mn)

Cash flow (ZAR Mn)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

7,8062,4804,7726,8609,688

Capital expenditure

3,2723,2661,9481,9722,070

Free cash flow (consolidated)

4,534-7862,8244,8887,618

Common dividends paid

7211,0751,6371,883—

Share repurchases

1378307260—

Net debt issued (repaid)

-1,686-1,947-5,664-2,28757

Free cash flow at the centre (company measure)

———4,0428,310

Adjusted FCF at the centre per share (ZAR cents)

———693891

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE % (IFRS, S&P)

11.694.791.062.621.46

ROE on headline earnings % (derived)

5.95.75.06.79.3

ROA % (S&P)

0.890.941.161.371.66

ROIC % (S&P)

1.801.691.282.042.09

Current ratio (x)

2.321.812.073.805.30

Debt to equity (x)

0.140.110.060.040.04

Net debt to EBITDA (x)

-0.450.55-0.78-1.77-4.16

Interest coverage EBIT/interest (x, derived)

2.382.312.876.149.86

Asset turnover (x)

0.280.310.350.360.36

Inventory turnover (x)

1.992.883.943.553.12

Mediclinic Region Details

Mediclinic regionRevenue growth %EBITDA margin %Margin change (bp)

Switzerland (Hirslanden; exited 1 Jul 2026)

0—170

Southern Africa (now 100% Remgro)

818.570

Middle East (50/50 with IHL)

1116.9270

Group

1015.5170

Share price (ZAR)

Share price (ZAR)FY2022FY2023FY2024FY2025FY2026

Closing price at 30 June

127.32147.05136.09158.20197.00

Financial-year high

151.76148.40164.01164.99—

Financial-year low

105.13122.07116.00129.28—

Return period (price only, approximate)

Return period (price only, approximate)Return %Basis

1 year (to 7 Oct 2026)

16.4

S&P 52-week change

Year to date 2026 (to 18 Sep 2026)

12.3

Business Day

About 3 years (30 Jun 2023 → 14 Oct 2026)

41.1

Derived: 207.48 / 147.05

About 5 years (30 Jun 2021 → 14 Oct 2026)

84.7

Derived: 207.48 / 112.31

Valuation Multiples

MultipleRemgroNotes

P/E on IFRS EPS

about 80x

Distorted by Mediclinic impairments (S&P: 81.1x)

P/HEPS

about 10.4x

Derived: 207.48 / 20.03

P/adjusted HEPS

about 11.4x

Derived: 207.48 / 18.19

Forward P/E (S&P consensus)

10.25x

S&P

P/INAV

about 0.68x

Derived

P/B (IFRS)

0.89x

S&P

EV/EBITDA (consolidated)

29.0x

S&P; not meaningful for a holding company

EV/Sales

1.94x

S&P

Ordinary dividend yield

about 2.9%

Derived: 595c / R207.48

Total yield incl. special

about 5.5%

Derived: 1,145c / R207.48

Dividend (ZAR cents per share)

Dividend (ZAR cents per share)FY2022FY2023FY2024FY2025FY2026

Interim ordinary

—808096173

Final ordinary

—160184248422

Total ordinary

150240264344595

Special

000200550

Total declared

1502402645441,145

Share repurchases (ZAR Mn)

Share repurchases (ZAR Mn)FY2022FY2023FY2024FY2025

Buybacks

1378307260

Capital Markets

ItemStatus

Moody's / S&P / Fitch issuer rating

No public rating identified in sources reviewed

National-scale ratings (e.g., GCR)

Not identified

Debt profile

Total consolidated debt R4.9bn at 30 Jun 2026: short-term R0.34bn, long-term R4.57bn incl. leases. Largely subsidiary-level borrowings (RCL, Rainbow, Wispeco)

Centre-level debt

Preference shares redeemed (FY2024–FY2025), lowering finance costs by R403m in FY2025

Analyst Conclusions

Management guidance (FY2026 results presentation, as summarised by Quartr)

  • Focus shifts from portfolio transformation to value compounding, using a strong balance sheet and a simplified portfolio.

  • Continued disciplined capital allocation, prioritising performance, growth opportunities and sustainability.

  • AI identified as a lever to accelerate strategic execution.

  • Dividend cover guidance maintained at 1.5x adjusted FCF.

  • Positioned for resilience and optionality amid macro and geopolitical volatility.

  • No quantitative FY2027 earnings guidance disclosed.

Consensus expectations

  • S&P consensus (2 analysts): forward P/E about 10.3x, implying forward EPS (headline-type) of roughly R19–R20, i.e., flat versus FY2026 reported HEPS.

  • 3-year EPS growth forecast: about 5.7% per year.

  • Market expectations therefore embed normalisation: the FY2026 once-offs (about R1.02bn) are not expected to repeat.

Bull case

  1. Clean, cash-rich, control-oriented portfolio. About R22.5bn of central cash (about R40 per share) plus 100% of MCSA, 57% of CIVH and a 50% joint venture in Air Products. Disciplined deployment or further distributions could compress the discount further from about 32%.

  2. Underlying earnings compounding. Adjusted HEPS grew 29% in FY2026. Fibre (Vumatel +15%), Middle East healthcare (+11% revenue, +270bp margin) and OUTsurance provide structural growth, while Rainbow and Heineken Beverages recover.

  3. Value marks from transactions. Vodacom's entry implied a Maziv pre-money value of about R30–36bn with an option for more. The Hirslanden/MCSA swap gave Remgro a $130m equalisation payment and exit from impaired Swiss assets.

Bear case

  1. High-water-mark earnings. About R1.02bn of once-offs (TotalEnergies refund, CIVH-related items) and a lower FirstRand dividend base mean FY2027 HE could stall or fall. Higher interest income on cash is temporary if cash is deployed or distributed.

  2. Structural discount persists. Dual-class control (over 40% of votes), opaque unlisted valuations and South African country risk may keep the discount at 30–40%. INAV per share grew only 4.6% in FY2026 despite record earnings.

  3. Concentrated South African risk after the Swiss exit. MCSA (NHI risk), RCL sugar (import exposure), poultry cycles and weak industrial output (August 2026 mining −12.7%) increase dependence on a low-growth domestic economy. The Middle East conflict adds risk to the remaining international healthcare leg.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhat to watch
Ex-dividend for the 422c final and 550c special21 Oct 2026Share-price adjustment; reinvestment flows
FY2026 Integrated Annual Report and remuneration reportOct–Nov 2026Updated stake percentages, INAV breakdown, risk register, pay outcomes
AGMNov 2026 (unconfirmed)Votes on remuneration policy; buyback authority
First consolidated MCSA numbersH1 FY2027 results (Mar 2027)Margin trajectory (18.5% H1 FY2026 base), debt consolidated, purchase-price allocation
Deployment of R22.5bn cashOngoingAcquisitions vs buybacks vs special dividends
RCL Foods corporate actionSpeculativeAny minority offer, sugar separation or Siqalo combination (unconfirmed)
Maziv performance and Vodacom option (+4.95%)OngoingVumatel growth, capex, option exercise as a valuation signal
Middle East situationOngoingMediclinic ME admissions and margins
Heineken Beverages trajectoryOngoingSustained profitability; valuation recovery
Discount to INAVOngoingNarrowing below about 30% would signal re-rating

Concluding analyst verdict

Remgro has largely completed the most consequential portfolio transformation in its 26-year listed history.

Exits: FirstRand, BAT, Grindrod, eMedia and the impaired Swiss hospital business.

Additions: full control of Mediclinic Southern Africa; Maziv co-control with Vodacom, which validated value and supplied capital.

Balance sheet: net cash of over R20bn.

The FY2026 numbers show that the restructuring is now flowing into earnings and cash. Headline earnings reached a record R11.14bn (+42%), adjusted HEPS rose 29%, FCF at the centre more than doubled, and over 90% of INAV reported earnings growth. The dividend policy of 1.5x adjusted FCF cover makes shareholder returns explicit and rules-based. The 550c special dividend shows a willingness to return realisation proceeds rather than hoard them.

The investment case is not without tension:

  • FY2026 benefited from roughly R1bn of non-recurring items, so FY2027 faces a demanding base.

  • INAV per share grew only 4.6% while earnings rose more than 40%. This suggests either conservative unlisted valuations or offsetting declines (OUTsurance's share price, RCL), and it underlines how much of the value now sits in assets marked by directors rather than by markets.

  • The portfolio is now more concentrated in South Africa just as domestic growth is soft and healthcare policy remains uncertain.

  • Governance concentration through class B voting shares remains a structural cap on the multiple.

On balance, at about 0.68x INAV, about 10x headline earnings and a total declared dividend yield of about 5.5%, the market is pricing Remgro as a well-capitalised but slow-compounding South African conglomerate. The asymmetric upside lies in what management does with R22.5bn of cash and whether MCSA and Maziv can compound at double-digit rates under direct control. The downside is cushioned by cash representing roughly 19% of market capitalisation.

Verdict: fundamentally improved and de-risked, with further discount narrowing contingent on capital-allocation execution over the next 12–24 months. Investors should anchor on adjusted HEPS (R18.19), adjusted FCF per share (891c) and INAV per share (R305.80) rather than IFRS EPS.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / appointmentBackground

Jannie Durand

Chief Executive Officer, executive director

CEO since 7 May 2012; previously Chief Investment Officer

Succeeded the late Thys Visser. Earlier: VenFin leadership and Remgro investment roles. Education reported as BAcc Hons (Stellenbosch) and MPhil (Oxford)

Neville Williams

Chief Financial Officer, executive director

—

Chartered accountant background

Mariza Lubbe

Chief Compliance and Operations Officer, executive director

Long-serving executive

—

Carel Vosloo

Chief Investment Officer; alternate executive director to the CEO

Joined Remgro March 2022 as Investment Executive; alternate director and Management Board member since 5 Apr 2024

RMB (2004–2022), including co-head of Corporate Finance and co-head of Investment Banking; RMB Executive member 2014–2022. BAcc Hons (Stellenbosch), MCom Tax (Wits), CA(SA), CFA

Pieter Neethling

Alternate director

——

Luché Joubert

Company Secretary

From 1 Nov 2024

—

Board of Directors

DirectorRoleClassificationNotes

Johann Rupert

Chair

Non-executive (not independent; controlling family)

Also chairs Richemont. Born 1950 (age 76; public record)

Sonja De Bruyn

Deputy Chair and Lead Independent Director

Independent non-executive

Deputy Chair from 1 Jul 2025; Audit & Risk Committee member

Jannie Durand

CEO

Executive

—

Neville Williams

CFO

Executive

—

Mariza Lubbe

Chief Compliance & Operations Officer

Executive

—

Anton Rupert

Director

Non-executive

Appointed Nov 2018; Rupert family

Josua Malherbe

Director

Non-executive

Former co-deputy chair (appointed 2014)

Gerrit Nieuwoudt

Director

Non-executive (listed as "ne" in Profile 2026)

Audit & Risk Committee member (2024 proposal)

Phumzile (P J) Moleketi

Director

Independent non-executive

Social & Ethics and Sustainability Committee from Sep 2024

Murphy Morobe

Director

Independent non-executive

Remuneration & Nomination Committee from 15 Jul 2025

K S (Sello) Rantloane

Director

Independent non-executive

Audit & Risk Committee member

Christine Ramon

Director

Independent non-executive

Appointed 27 Nov 2025. Former AngloGold Ashanti CFO (8 years, incl. a year as interim CEO); NED of Vodafone plc and Clicks Group

Carel Vosloo

Alternate to CEO

Executive alternate

—

Pieter Neethling

Alternate

——

Major Shareholders

ShareholderStakeDateSource

Rupert family (via unlisted class B shares)

Over 40% of voting rights

2026

BusinessTech, Mar 2026

Public Investment Corporation (Government Employees Pension Fund)

16.04% of ordinary shares

30 Jun 2025

Profile's Handbook 2026

Ninety One SA (clients)

5.10% (Jun 2025); 5.0156% after crossing the 5% threshold on 17 Aug 2026

2025–2026

Profile's Handbook; BusinessTech, Aug 2026

Fairtree Asset Management

5.01%

30 Jun 2025

Profile's Handbook 2026

Institutions (aggregate)

49.50%

Oct 2026

S&P Global via StockAnalysis

Insiders (aggregate, ex-B-share voting)

1.65%

Oct 2026

S&P Global via StockAnalysis

Competitive Landscape

Key Competitors

PeerTypeRelative positioning vs Remgro

Reinet Investments

Rupert-family international investment holding (Luxembourg; JSE-listed)

Sister vehicle; international private equity and credit; not a direct competitor for South African assets

Hosken Consolidated Investments (HCI)

South African diversified holding company (media, gaming, energy, property)

Smaller; overlaps in media (eMedia, now unbundled by Remgro)

African Rainbow Capital Investments (ARC)

B-BBEE investment holding company (financial services, diversified)

Smaller; trades at a deep NAV discount; competes for financial services and telecom deals

Brait

Investment holding (Virgin Active, Premier Group, New Look)

Smaller and more leveraged; overlaps in consumer goods (Premier vs RCL)

PSG Group (unbundled 2023) / Zeder

Former Stellenbosch peer holding companies, now largely unbundled

Illustrates the "unbundle to close the discount" route

Sabvest Capital

Small diversified holding company

Much smaller; similar long-term-holder model

Global/local private equity (Ethos, Old Mutual Alternatives, international PE)

Private capital

Compete for control positions in South African unlisted assets

Competitor Detail

Remgro investeeSegmentNamed direct competitors

Mediclinic Southern Africa

Private hospitals

Netcare, Life Healthcare, National Hospital Network members

Rainbow Chicken

Poultry

Astral Foods, Quantum Foods, Sovereign Foods, imports

RCL Foods (Groceries/Baking)

Packaged foods and bread

Tiger Brands, Premier Group (Brait), Pioneer Foods (PepsiCo), Libstar

RCL Foods (Sugar)

Sugar

Tongaat Hulett, Illovo Sugar, imports

Siqalo Foods

Spreads and oils

Willowton Group, Upfield, private-label brands

Heineken Beverages

Beer, cider, spirits

South African Breweries (AB InBev), Diageo

Maziv (Vumatel/DFA)

Fibre

Openserve (Telkom), Frogfoot, MetroFibre, Liquid Intelligent Technologies

OUTsurance

Short-term insurance

Santam, Hollard, Discovery Insure, King Price, Old Mutual Insure

Air Products SA

Industrial gases

Afrox (Linde)

TotalEnergies SA

Fuel retail

Vivo Energy (Engen/Shell), Astron Energy, Sasol, BP

Wispeco

Aluminium extrusions

Hulamin Extrusions, imports

Competitor Detail — Latest fiscal year

MetricRemgro

Latest fiscal year

FY Jun 2026

Revenue (ZAR Bn)

51.0

Revenue growth %

0.9

Headline earnings growth %

42.3

EBITDA margin % (consolidated)

9.8

Discount to NAV %

c.32 (Oct 2026, derived)

Recent Developments

Date discrepancy flag: * FY2026 results publication is reported as Friday 18 September 2026 (Daily Investor, Business Day, BusinessTech). Pre-results coverage and S&P list 21 September as the earnings date, and Quartr lists the event on 23 September. Most likely, the SENS was released on 18 September and the presentation was held on 21 September.

Company Snapshot

$2,833.9M

Revenue

173

Employees

1940

Founded

Stellenbosch, South Africa

Headquarters

SWOT Analysis

Strengths

  • Earnings momentum. HEPS rose 38.4% in FY2025 and 42.2% in FY2026 to R20.03. Excluding once-offs, adjusted HEPS still grew 29.1% to R18.19 (FY2026 results).
  • Fortress balance sheet. Consolidated net cash was R20.7bn at 30 June 2026 and debt/equity 0.04x (S&P). Cash at the centre was R22.5bn post year-end (results presentation).
  • Cash generation. FCF at the centre more than doubled to R8.31bn (+105.6%) in FY2026; adjusted FCF per share rose 28.6% to 891c.
  • Partner quality. Co-ownership with MSC (healthcare), Vodacom (fibre), Heineken (beverages), Air Products and TotalEnergies supplies capital, technology and governance discipline.
  • Disciplined realisations. The FirstRand exit realised R8.47bn in 2026. The Mediclinic swap gave Remgro full MCSA control for $947m versus Hirslanden's $1,077m, plus a $130m equalisation distribution.
  • Broad-based portfolio improvement. Over 90% of INAV reported earnings growth in FY2026; more than 80% did so in FY2025.

Weaknesses

  • Persistent discount to INAV. 45.9% at June 2025 and about 32% in October 2026 (derived). Value creation at investee level is only partly reflected in the share price.
  • Low IFRS returns. ROE was 1.46% in FY2026 on an IFRS basis (S&P), and EPS fell 56.5% because of Mediclinic Swiss impairments.
  • Weak consumer assets. RCL's headline earnings fell 30–31% in H1 FY2026 on sugar; Heineken Beverages was impaired by about R10bn in 2024 (Heineken write-down).
  • Valuation opacity. A rising share of unlisted assets (MCSA, Maziv, Siqalo, Air Products) relies on directors' valuations; INAV per share grew only 4.6% in FY2026 despite 42% HE growth.
  • Dual-class control. The Rupert family's class B shares carry over 40% voting control, limiting minority influence and takeover discipline.
  • Flat consolidated revenue. +0.3% (FY2025) and +0.9% (FY2026) indicates limited organic top-line growth in subsidiaries.

Opportunities

  • Maziv growth plus Vodacom synergies. Vumatel revenue grew 15.4% in H1 FY2026. Vodacom holds an option on a further 4.95%, signalling an upward valuation reference point.
  • Full control of MCSA. 100% ownership allows Remgro to drive efficiency and capital allocation directly. MCSA's EBITDA margin was 18.5% in H1 FY2026.
  • Deployment of R20bn+ cash. Bolt-ons, buybacks (none disclosed in FY2025) or further special dividends.
  • RCL corporate action. Market speculation about a minority buyout, sugar separation or a merger with Siqalo (unconfirmed) could unlock value.
  • Middle East healthcare. Mediclinic ME revenue grew 11% and margins rose 270bp in H1 FY2026.
  • AI-enabled performance improvement across investees, as stated in the FY2026 results.

Threats

  • Geopolitics. The 2026 Middle East conflict complicates Mediclinic's UAE operations and pressured asset prices (Old Mutual Aperture, Mar 2026).
  • South African macro and policy. Weak GDP, mining contraction (August 2026 output −12.7% YoY per Business Day), NHI uncertainty and sugar tariff failures.
  • Commodity and input-cost cycles. Maize and soya prices for Rainbow, global sugar prices for RCL, oil for TotalEnergies (FY2025 −R359m from stock revaluations).
  • Non-repeatable FY2026 items. About R1.02bn of once-offs (TotalEnergies refund, CIVH-related items) create a tough base for FY2027.
  • Competition-law constraints. The Vodacom/Maziv deal took four years, including a 2024 Tribunal prohibition; future fibre or healthcare consolidation faces similar scrutiny.
  • Rand volatility. This affects the ZAR value of USD-denominated healthcare assets (MCSA bought in USD) and offshore earnings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
27 Jun 2025Board changes announced: De Bruyn named Deputy Chair from 1 Jul 2025 after Robertson and Mageza retireGovernance renewal
27 Jun 2025Voluntary announcement of the eMedia agreement and planned unbundlingPortfolio simplification
15 Jul 2025Murphy Morobe appointed to the Remuneration & Nomination CommitteeGovernance
18 Jul 2025Revised Vodacom/Maziv terms published: aggregate price about R12.2bn; longstop extendedDeal de-risking
15 Aug 2025Competition Appeal Court approves Vodacom/MazivRemoves the main regulatory hurdle
8 Sep 2025eMedia unbundling declaration and finalisation announcementCorporate action
Sep 2025Final BAT shares sold (1.25m shares, R1.21bn)Exit of the tobacco legacy
23 Sep 2025FY2025 results: HE +38.6% to R7.83bn; HEPS R14.09; INAV R292.34; ordinary DPS 344c plus 200c specialEarnings recovery confirmed
26–30 Sep 2025eMedia shares distributed (29 Sep); closing prices and ratio correction announced (41.96443 per 100)Corporate action completion
Oct 2025FY2025 Integrated Annual Report publishedDisclosure
26 Nov 2025All Maziv conditions precedent fulfilled (ICASA approval incl. I-ECNS licence)Deal closes
27 Nov 2025AGM: all resolutions passed. Christine Ramon appointed independent NEDGovernance
1 Dec 2025Maziv transaction implemented; Vodacom pays R6.1bn cash and contributes R4.9bn of assetsCash and value crystallisation
1 Dec 2025Cautionary: in-principle agreement with IHL to split Mediclinic. Mediclinic H1 revenue $2.56bn (+10%), adjusted EBITDA $397m (+23%)Major portfolio change
16 Jan 2026Further cautionary on MediclinicProcess update
27 Feb 2026Further cautionary on MediclinicProcess update
11 Mar 2026Disposal of 51.97m FirstRand shares for R4.878bn announcedLiquidity build
13 Mar 2026H1 trading statement: HEPS expected +36% to +41%Guidance
25 Mar 2026Interim results: HE +38.8% to R5.175bn; HEPS 931c; interim DPS 173c (+80.2%); INAV R297.03Momentum confirmed. Middle East conflict flagged as a risk to Mediclinic UAE
31 Mar 2026Category 2 announcement: Mediclinic restructuring implementation agreement signed 30 Mar 2026; cautionary withdrawnDefinitive agreement
10 Apr 2026Executive share sales on vesting of awards (Durand R33.6m)Insider dealing (incentive-related)
Apr 2026Remaining 39.6m FirstRand shares sold for R3.59bn; exit completePortfolio pivot complete
29 May 2026Mediclinic FY Mar 2026 summary: adjusted EBITDA $842m (+14%); statutory loss $733m after $1.24bn impairmentsSwiss impairment drives Remgro's IFRS EPS decline
1 Jul 2026Mediclinic restructuring implemented: Remgro owns 100% of MCSA; Hirslanden goes to IHL; Remgro receives $130mNew healthcare structure
20 Jul 2026Media coverage of the CEO's cumulative R227.6m pay over 14 yearsRemuneration scrutiny
17 Aug 2026Ninety One crosses 5% (5.0156%)Shareholder register
11 Sep 2026FY2026 trading statement: HEPS R19.30–R20.71 (+37% to +47%)Guidance
18 Sep 2026FY2026 results: HE R11.14bn (+42.3%); HEPS R20.03; EPS R2.59 (−56.5%); INAV R305.80; DPS 595c plus 550c special; share +3.2% to R202.15Record earnings; large special dividend
21–23 Sep 2026Results presentation and media interviews (CIO Vosloo); "next phase of value unlock" messageStrategic messaging
21 Oct 2026 (scheduled)Ex-dividend date for the final (422c) and special (550c) dividendsUpcoming

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Income Statement: Revenue & Gross Profit: Revenue rose from ZAR 41,876 Mn in FY2022 to ZAR 51,010 Mn in FY2026.
Remgro Limited — Income Statement: Revenue & Gross Profit
Series (ZAR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue41,87648,15150,42450,55951,010
Gross profit15,81017,33918,23818,89420,365

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Remgro Limited SENS announcements: FY2025 audited results (23 Sep 2025); H1 FY2026 interim results (25 Mar 2026); Mediclinic restructuring announcements (1 Dec 2025, 27 Feb 2026, 31 Mar 2026, 1 Jul 2026); Mediclinic FY Mar 2026 summary (29 May 2026); Maziv conditions precedent (26 Nov 2025); eMedia unbundling (27 Jun 2025, 8 Sep 2025, 26 & 30 Sep 2025); board changes (5 Apr 2024, 18 Sep 2024, 27 Jun 2025, 15 Jul 2025, 27 Nov 2025). Accessed via sharedata.co.za / senspdf.jse.co.za
  2. Remgro FY2023 annual financial statements (JSE, REMJun2023.pdf)
  3. Vodacom Group SENS: update on the acquisition of a 30% interest in Maziv (26 Nov 2025)
  4. Profile's Stock Exchange Handbook, 2026 Issue 1 (p.170) and 2025 Issue 4 (p.178): Remgro Ltd entry
  5. S&P Global Market Intelligence via StockAnalysis.com: Remgro (JSE:REM) income statement, balance sheet, cash flow, ratios and statistics (updated 18 Sep – 7 Oct 2026)
  6. Business Day: "Remgro hikes dividend by more than 70% after strong year" (21 Sep 2026); "Remgro rewards shareholders after strong first half" (25 Mar 2026); "Remgro and IHL to restructure their interests in Mediclinic" (1 Dec 2025)
  7. Daily Investor: FY2026 results coverage (18 Sep 2026); FY2026 trading statement (Sep 2026); Mediclinic restructuring (Jul 2026); Maziv coverage (2025–2026); director dealings (Apr 2026); Carel Vosloo appointment (2024)
  8. BusinessTech: FY2026 dividend coverage; Ninety One 5% stake (17 Aug 2026); FirstRand disposal (13 Mar 2026); FY2025 dividend coverage
  9. EWN: "Remgro posts strong FY2026 earnings as portfolio transformation reaches key milestone" (21 Sep 2026)
  10. Quartr: Remgro H2 2026 earnings summary (Sep 2026)
  11. Old Mutual Private Clients, "Aperture: Remgro HY 2026 Results" (27 Mar 2026)
  12. PSG Research, Remgro company update report (10 Nov 2025)
  13. Financial Mail: RCL Foods coverage (Mar 2025, Mar 2026)
  14. FilingReader summaries of Remgro SENS (Sep 2025, May 2026, Jul 2026)
  15. IOL / Business Report: FY2025 results and Mediclinic restructuring coverage (Sep & Dec 2025)
  16. Alliance News via Morningstar / AJ Bell: Mediclinic take-private completion (May 2023); The Namibian (2023)
  17. Fin24: "New CEO for Remgro" (May 2012)
  18. africa.com: Remgro FirstRand exit and portfolio strategy (2026)
  19. Ground News / Billionaires.Africa: CEO cumulative remuneration (Jul 2026)
  20. MarketScreener: Remgro insider and board-change news log
  21. Encyclopaedic summaries of Remgro corporate history (citing Remgro 2015 Annual Report)

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.